2027 ICD-10-CM Diagnosis Code Q85.02Neurofibromatosis, type 2

ICD-10-CM Codes›Q00-Q99›Q80-Q89›Q85

ICD-10-CM Q85.02
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

Q85.02 is a billable ICD-10-CM diagnosis code for neurofibromatosis, type 2. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 91 through 93. The code is exempt from POA reporting. Coders also document this condition as benign neoplasm of vestibulocochlear nerve. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Nervous system congenital anomalies.

For Medicare Advantage risk adjustment, Q85.02 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
Q85.02
Billable Status
Yes — Valid for Submission
Code Describes
Neurofibromatosis, type 2
Short Description
Neurofibromatosis, type 2
Same as the full description in the CMS dataset.
Parent Code
Q85.0
Neurofibromatosis (nonmalignant)

Code Classification

ChapterQ00-Q99Congenital malformations, deformations and chromosomal abnormalities
SectionQ80-Q89Other congenital malformations
CategoryQ85Phakomatoses, not elsewhere classified
This CodeQ85.02Neurofibromatosis, type 2

Present on Admission (POA)Billing

Q85.02 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review the other POA exempt codes in Other congenital malformations (Q80-Q89).

Medicare Risk Adjustment (HCC)Billing

Q85.02 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 23— Prostate, Breast, and Other Cancers and Tumors
Payment HCC · PY 2027 one of 234 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.186
community, non-dual, aged · ranges 0.186–0.237 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 12
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 12 · ESRD (V21): HCC 12 · ESRD (V24): HCC 12
ESRD V21 weights: 0.046 dialysis, 0.156–0.194 functioning graft · ESRD V24 weights: 0.045 dialysis, 0.162–0.219 functioning graft
Part D (RxHCC)
Not mapped
Q85.02 does not risk-adjust in the RxHCC prescription drug model

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Benign neoplasm of vestibulocochlear nerve
  • Mosaic neurofibromatosis type 2
  • Neurofibromatosis type 2
  • Schwannoma of cranial nerve

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to Q85.02: its own notes plus those printed at Q85 and Chapter 17. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • Acoustic neurofibromatosis

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From Q85 Phakomatoses, not elsewhere classified applies to 11 codes
  • ataxia telangiectasia [Louis-Bar] (G11.3)
  • familial dysautonomia [Riley-Day] (G90.1)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Chapter 17 (Q00-QA1) Congenital malformations, deformations and chromosomal abnormalities applies to 900 codes
  • inborn errors of metabolism (E70-E88)

Notes

General instructions on how these codes are used.

From Chapter 17 (Q00-QA1) Congenital malformations, deformations and chromosomal abnormalities applies to 900 codes
  • Codes from this chapter are not for use on maternal records

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name Q85.02, its category, or a range that includes it.

Excludes1 3

These codes carry an Excludes1 note naming Q85.02: they are not reported together with it, unless the two conditions are unrelated.

  • D33 Benign neoplasm of brain and other parts of central nervous system
    neurofibromatosis (Q85.0-) names Q85.0-, which includes this code
  • D36.1 Benign neoplasm of peripheral nerves and autonomic nervous system
    neurofibromatosis (Q85.0-) names Q85.0-, which includes this code
  • D48 Neoplasm of uncertain behavior of other and unspecified sites
    neurofibromatosis (nonmalignant) (Q85.0-) names Q85.0-, which includes this code

Excludes2 1

These codes carry an Excludes2 note naming Q85.02: its condition is not part of those codes, and both may be reported when the patient has both.

  • Q07 Other congenital malformations of nervous system
    neurofibromatosis (nonmalignant) (Q85.0-) names Q85.0-, which includes this code

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR MAL004
Nervous system congenital anomalies
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Neurofibromatosis 2

    an autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (neurilemmoma) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. the disease has been linked to mutations of the nf2 gene (genes, neurofibromatosis 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.

Patient EducationClinical

Neurofibromatosis

Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects how nerve cells form and grow. It causes tumors to grow on nerves. You can get neurofibromatosis from your parents, or it can happen because of a mutation (change) in your genes. Once you have it, you can pass it along to your children.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert Q85.02 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
237.72 Neurofibromatosis typ II
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About Q85.02Overview

What is the ICD-10 code for neurofibromatosis, type 2?

The ICD-10-CM code for neurofibromatosis, type 2 is Q85.02 (sometimes written as Q8502). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is Q85.02 (Neurofibromatosis (nonmalignant)) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report neurofibromatosis, type 2 on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does Q85.02 group to?

When neurofibromatosis, type 2 is the principal diagnosis on an inpatient stay, it groups to MS-DRG 91, 92, 93, with relative weights from 0.7783 to 1.7050 depending on complications. Higher weights mean higher Medicare reimbursement.

Is Q85.02 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for neurofibromatosis, type 2 on inpatient claims. The code appears in the Other congenital malformations (Q80-Q89) range of the CMS exempt list.

Can Q85.02 be reported with G11.3?

Not as a rule. The Excludes1 note at Q85, which applies to Q85.02, lists "ataxia telangiectasia [Louis-Bar] (G11.3)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What HCC is Q85.02?

Q85.02 (neurofibromatosis, type 2) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.

Does Q85.02 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, Q85.02 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.